Xenon Pharmaceuticals (XENE) Q2 2024 earnings summary

Executive summary

• Advanced late-stage clinical programs for azetukalner in epilepsy and MDD, with multiple Phase 3 trials ongoing and new preclinical Kv7 and NaV1.7 candidates nominated for IND-enabling studies.

• Phase III X-TOLE2 epilepsy study top-line data expected in H2 2025, with NDA submission planned upon positive results; MDD Phase 3 trial initiation set for H2 2024.

• The company has not generated product revenue and funds operations through equity sales, collaborations, and debt, reporting a net loss of $105.9 million for the first half of 2024.

• Sufficient cash, cash equivalents, and marketable securities of $850.6 million as of June 30, 2024, projected to fund operations into 2027.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $850.6 million as of June 30, 2024, down from $930.9 million at year-end 2023.

• Net loss was $57.9 million for Q2 2024, compared to $47.5 million in Q2 2023; net loss for the first half of 2024 was $105.9 million.

• Operating expenses rose to $69.1 million in Q2 2024, driven by higher R&D and G&A costs.

• Interest and other income increased to $10.8 million in Q2 2024, reflecting higher balances and yields.

• Shareholders' equity was $844.0 million as of June 30, 2024.

Outlook and guidance

• X-TOLE2 Phase III epilepsy study top-line data expected in H2 2025; NDA submission to follow positive results.

• First Phase III MDD trial to initiate in H2 2024, with staggered starts for subsequent trials; data to be released as each study completes.

• Multiple IND filings for new Kv7, NaV1.7, and NaV1.1 assets targeted for 2025.

• Cash runway projected to fund operations into 2027, supporting late-stage and preclinical development.